Insight

GLP-1, obesity, and the global cost curve.

GLP-1 medicines are changing more than a pharmaceutical category. They are changing how health systems, employers, insurers, food companies, and consumers think about obesity, prevention, adherence, and long-term cost.

The commercial question is not only whether demand exists. It is who sustains usage, who pays, which trade-offs matter, and how behaviour changes once early curiosity meets real constraints.

A human-anchored synthetic research design can test those trade-offs across markets: affordability, side effects, provider trust, stigma, perceived efficacy, and willingness to change adjacent consumption patterns.

The useful signal comes from grounding the simulation in real decision context before scaling it. That is what separates market insight from category noise.